Technology for spasticity and recovery.

Spasticity and stiffness are two types of increased muscle tone with different causes and characteristics. Spasticity is speed-dependent and appears in upper motor neuron lesions such as stroke, cerebral palsy or multiple sclerosis. Stiffness, on the other hand, offers constant resistance regardless of speed, and is characteristic of diseases such as Parkinson's. Although both limit movement and can cause pain and deformities, they respond to different treatments.

Neuromodulation can make a real difference in people with spasticity: from opening a window of lower tone that enhances work in physiotherapy and other therapies, to reducing pain, facilitating daily activities and improving the quality of life of the person and those who accompany them.

Neurostimulation is contraindicated in people with a demand cardiac pacemaker, implanted defibrillator, or any other active electrical implant. It is also contraindicated when there is a metal implant directly under the stimulation area, a cancerous lesion in the area of ​​use, or an active inflammatory, infectious or skin process in that area. Caution and prior medical evaluation is recommended in people with epilepsy, heart problems, high spinal cord injury (T6 or higher) or reduced skin sensitivity in the application area. Its use during pregnancy has not been established as safe.

The Exopulse is a neuromodulation suit that simultaneously stimulates multiple muscle groups at low intensity to regulate overall postural tone and reduce spasticity. It is used in 60-minute sessions, after which there may be a window of lower tone that facilitates subsequent therapeutic work. Bioness, on the other hand, is a functional electrostimulation system that acts locally and synchronized with movement, stimulating the peroneal nerve at the precise moment of walking to activate dorsiflexion of the foot. In many cases they are not exclusive but are complementary.

Yes. Exopulse has specific clinical evidence in fibromyalgia. A randomized, double-blind, placebo-controlled clinical trial demonstrated that daily 60-minute sessions for 2 weeks significantly reduced pain, fatigue, anxiety, and overall disease impact, with results that continued to improve after 4 weeks of use. Fibromyalgia is, in fact, one of the recognized indications for the device, precisely because its ability to stimulate multiple areas of the body simultaneously makes it especially useful in a diffuse pain condition like this.

Bioness L300 Go is specifically designed for foot drop secondary to an upper motor neurone lesion, such as stroke or multiple sclerosis. A sensor automatically detects the relevant point in the gait cycle and stimulates the peroneal nerve to activate dorsiflexion at precisely the right moment, improving gait pattern and reducing the risk of falls. In a purely peripheral nerve injury, such as a severed or crushed common peroneal nerve, response may be more limited because the damaged nerve may not conduct the electrical stimulus as effectively. In these cases, an assessment session is advisable to confirm a response before recommending the device.